We demonstrated that targeting the prion‐like domain of EBNA1 inhibits protein aggregates formation, promots SRRM1 alternative splicing and inhibits nasopharyngeal cancer progression. This evidence concerns the gene SRRM1 and nasopharyngeal carcinoma.